177Lu is a beta-emitting radioisotope, and 177Lu-PSMA-617 targets overexpressed PSMA and has demonstrated excellent therapeutic response in metastatic prostate cancer [84]. Here, FOLH1 is linked to metastatic prostate carcinoma.